Bionic eyes are no longer the stuff of science fiction; after years of research, the first bionic eye is poised to hit the U.S. market. A company called Second Sight Medical Products has developed their Argus II Retinal Prosthesis System which consists of 60 electrodes. Implanted in the retina, and with glasses fitted with a special mini-camera, the retinal prosthesis would restore sight to those with retinitis pigmentosa, a rare genetic disease affecting some 100,000 people in the U.S. The Argus is poised for FDA approval soon, and after that, bionic eyes will become commercial available.
Kathleen Owings tells ThinkAdvisor about the two kinds of client reactions to the pandemic and leading a nearly all-male platoon.
Many clients have little or no protection for their ability to earn a paycheck.
A marketing veteran takes on… the question.
Sponsored by NGL
Help your clients plan for their future now so final expenses don’t overwhelm their loved ones later.
Don’t miss crucial news and insights you need to make informed investment advisory decisions. Join ThinkAdvisor.com now!
- Free unlimited access to ThinkAdvisor.com which provides advisors, like you, with comprehensive coverage of the products, services and trends necessary to guide your clients in making critical wealth, health and life decisions.
- Exclusive discounts on ALM and ThinkAdvisor events.
- Access to other award-winning ALM websites including TreasuryandRisk.com and Law.com.
Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.